Research programme: cancer therapeutics - Intezyne

Drug Profile

Research programme: cancer therapeutics - Intezyne

Alternative Names: Daunorubicin - Intezyne; Epithilone-D - Intezyne; IT-121; IT-143; IT-145; IT-147

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intezyne
  • Class Alkaloids; Anthracyclines; Camptothecins; Gene therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; DNA topoisomerase I inhibitors; Gene transference; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 15 Apr 2016 Pharmacodynamics data from preclinical trial in Solid tumours released at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 21 Jun 2013 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top